Post by Nadica (She/Her) on Aug 4, 2024 3:12:14 GMT
NIH Starts Testing Nasal COVID-19 Vaccine in US - Published Aug 2, 2024
Aclinical trial evaluating the safety and effectiveness of a nasal vaccine candidate known as MPV/S-2P to protect against COVID-19 recently began enrolling participants, the US National Institutes of Health (NIH) announced.
MPV/S-2P is a live murine pneumonia virus vector modified with a SARS-CoV-2 spike protein, according to ClinicalTrials.gov. Prior research suggested that the investigational nasal vaccine was safe when given to nonhuman primates. It also prompted robust immune responses in the animals, particularly in the nose and respiratory tract.
The phase 1 trial is the first that the NIH’s National Institute of Allergy and Infectious Diseases is conducting as part of Project NextGen, a more than $5 billion initiative to generate new tools against COVID-19. The study’s researchers are planning to enroll 60 adults aged 18 to 64 years who have already received 3 doses of an available messenger RNA, or mRNA, COVID-19 vaccine across 3 US sites.
Aclinical trial evaluating the safety and effectiveness of a nasal vaccine candidate known as MPV/S-2P to protect against COVID-19 recently began enrolling participants, the US National Institutes of Health (NIH) announced.
MPV/S-2P is a live murine pneumonia virus vector modified with a SARS-CoV-2 spike protein, according to ClinicalTrials.gov. Prior research suggested that the investigational nasal vaccine was safe when given to nonhuman primates. It also prompted robust immune responses in the animals, particularly in the nose and respiratory tract.
The phase 1 trial is the first that the NIH’s National Institute of Allergy and Infectious Diseases is conducting as part of Project NextGen, a more than $5 billion initiative to generate new tools against COVID-19. The study’s researchers are planning to enroll 60 adults aged 18 to 64 years who have already received 3 doses of an available messenger RNA, or mRNA, COVID-19 vaccine across 3 US sites.